The benefits of inhibiting PARP in BRCA-mutated ovarian or breast cancer are well documented (Fong et al, 2009; Audeh et al, 2010; Tutt et al, 2010; Kaye et al, 2012; Sandhu et al, 2013; Lee et al, 2014b). This evidence concerns the gene PARP1 and breast cancer.